Volastra
Maeve Morse-Seaverns is an experienced professional currently serving as the Associate Director of Business & Portfolio Strategy at Volastra Therapeutics since May 2024. Prior to this role, Maeve held positions as Senior Manager in Commercial Development and Market Intelligence at the same company, and participated as a Columbia Venture Fellow from November 2022 to May 2024. Additional experiences include a Venture Fellow position at T.Rx Capital, an MBA Internship in New Product Planning at Intellia Therapeutics, and various consulting roles at Trinity Life Sciences. Early career experiences include internships in healthcare at Fidelity Investments and the Fidelity Health Marketplace, along with a role as a Water Safety Instructor in Sherborn. Maeve is currently pursuing an MBA at Columbia Business School, having obtained an undergraduate degree from Bowdoin College.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.